Search
Neuronetics Inc
STIMAdd to Watchlist
1.280USD
-0.020-1.54%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
89.07MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-1.54%
5 Days
-22.66%
1 Month
-8.57%
6 Months
-35.68%
Year to Date
-7.25%
1 Year
-69.67%
TradingKey Stock Score of Neuronetics Inc
Currency: USD Updated: 2026-05-15Key Insights
Neuronetics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 91 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.33.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Neuronetics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Neuronetics Inc Highlights
StrengthsRisks
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 109.06% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 149.16M.
Fairly Valued
The company’s latest PE is -2.37, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 47.87M shares, decreasing 13.05% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 52.91K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.84.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
4.333
Target Price
+233.33%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Neuronetics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Neuronetics Inc Info
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Ticker SymbolSTIM
CompanyNeuronetics Inc
CEOMr. Keith J. Sullivan
Websitehttps://neurostar.com/neuronetics/
Related Instruments
-1.32%
-2.23%
-1.62%
-0.49%
-1.30%
+0.41%
-1.57%
-1.05%
-2.22%
-1.04%
-1.59%
-3.29%
-1.06%
-6.97%
+0.04%
-0.76%
-0.71%
+1.31%
-1.21%
-0.56%Popular Instruments
102.160
+3.297 (+3.33%)
300.230
+2.020 (+0.68%)
225.320
-10.420 (-4.42%)
4538.710
-111.520 (-2.40%)
482.020
-7.101 (-1.45%)
1407.610
+24.890 (+1.80%)
724.660
-51.350 (-6.62%)
396.780
-4.290 (-1.07%)
78134.970
-96.030 (-0.12%)
422.240
-21.060 (-4.75%)
